The public-healthcare-setting psilocybin RCT for TRD reports positive primary endpoint within 8 weeks, strengthening reimbursement arguments.

A clinical trial — a carefully controlled test on real patients — running psilocybin therapy inside an ordinary public healthcare setting has hit its main success target for treating hard-to-treat depression. This matters because it shows the therapy can work outside fancy research labs, which is the key argument for getting health insurers to pay for it.

Real-world-setting data is exactly what's needed to move beyond academic silos. The signal's existence implies near-term reporting.